Biomarker-guided therapy in NSCLC and beyond

In this episode, Dr. Lizza Hendriks, MD, PhD, delves into a challenging case involving a 40-year-old male with a history of psychosis. Despite being asymptomatic and off medication, he presents with concerning symptoms: a persistent cough, dyspnea, and a chest X-ray revealing a tumor in the left perihilar region. PET CT imaging further identifies multiple small lung nodules, a peripheral left tumor, and bone metastasis. Learn about diagnostic challenges, tissue-based testing, surgical interventions, choosing targeted therapies, and how brain imaging considerations are crucial for optimal management.

This series of 3 podcasts is accredited for 0.25 AMA Type 1 Credit(s) To learn more about the full program, visit targeted-therapies-lung-cancer.ime.springerhealthcare.com for additional resources, including the webinar and downloadable patient case studies.

This program is made possible thanks to an independent educational grant from Roche and Illumina.

REFERENCES

• Solomon, B. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. JCO 2024 May 31:JCO2400581. doi: 10.1200/JCO.24.00581. Online ahead of print


• Mok, T. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020 Aug;31(8):1056-1064. doi: 10.1016/j.annonc.2020.04.478. Epub 2020 May 11.


• Camidge, D. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. JTO 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16